Current Report Filing (8-k)
20 September 2016 - 6:32AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported)
September
15, 2016 (September 19, 2016)
HEMISPHERX
BIOPHARMA, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
0
- 27072
|
|
52-0845822
|
(state
or other jurisdiction
|
|
(Commission
|
|
(I.R.S.
Employer
|
of
incorporation)
|
|
File
Number)
|
|
(Identification
No.)
|
1617
JFK Boulevard, Suite 500, Philadelphia, PA
|
|
19103
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant's
telephone number, including area code:
(215) 988-0080
1617
JFK Boulevard, Suite 500, Philadelphia, PA 19103
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
8.01 Other Matters.
On
September 15, 2016, we received written notice from the NYSE MKT LLC that we were back in compliance with the continued listing
standards set forth in Section 1003(f)(v) of the NYSE MKT Company Guide referenced in the Exchange’s letter dated March
15, 2016. The Company will be subject to NYSE Regulation’s normal continued listing monitoring. However, in accordance with
Section 1009(h) of the Company Guide, if the Company is again determined to be below any of the continued listing standards within
12 months of the date of this letter, NYSE MKT will examine the relationship between the two incidents of noncompliance and re-evaluate
the Company’s financial recovery from the first incident. NYSE Regulation will then take appropriate action, which depending
on the circumstances, may include truncating the compliance procedures described in Section 1009 of the Company Guide or immediately
initiate delisting procedures.
On
September 19, 2016, we issued a press release regarding our regained compliance with the continued listing requirements of the
NYSE MKT. A copy of the press release is furnished hereto as Exhibit 99.1.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release dated September 19, 2016
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
HEMISPHERX
BIOPHARMA, INC.
|
|
|
September
19, 2016
|
By:
|
/s/ Thomas K. Equels
|
|
|
Thomas
K. Equels, CEO
|
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From Apr 2024 to May 2024
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From May 2023 to May 2024